Trials / Recruiting
RecruitingNCT07106879
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Pre-screening Survey for Metabolic, Cardiovascular, Obesity, Mental Health, and Endocrine Trial Eligibility (DOVE-MET-COME-100)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,000 (estimated)
- Sponsor
- Clindove Research LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.
Detailed description
Eligible participants will undergo screening procedures including laboratory assessments and health questionnaires to determine their suitability for further evaluation in metabolic and/or psychiatric sub-studies. The study does not include any investigational intervention.
Conditions
- Cardiovascular Diseases
- Metabolic Syndrome
- Obesity
- Prediabetes
- Mental Health Disorders
- Endocrine Dysfunction
- Type 2 Diabetes Mellitus (T2DM)
- Chronic Kidney Disease (CKD)
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood Work | Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays. |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2030-07-01
- Completion
- 2030-12-01
- First posted
- 2025-08-06
- Last updated
- 2025-08-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07106879. Inclusion in this directory is not an endorsement.